Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
Pauline Maisonnasse, Jérémie Guedj, Vanessa Contreras, et al.
Nature (2020) Vol. 585, Iss. 7826, pp. 584-587
Open Access | Times Cited: 334

Showing 26-50 of 334 citing articles:

SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota
Harry Sokol, Vanessa Contreras, Pauline Maisonnasse, et al.
Gut Microbes (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 89
Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial
Raymond C.S. Seet, Amy M.L. Quek, Delicia Shu Qin Ooi, et al.
International Journal of Infectious Diseases (2021) Vol. 106, pp. 314-322
Open Access | Times Cited: 88
In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2
Mathieu Gendrot, Julien Andréani, Priscilla Jardot, et al.
Molecules (2020) Vol. 25, Iss. 21, pp. 5064-5064
Open Access | Times Cited: 87
A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes
Yu Guo, Lisu Huang, Guangshun Zhang, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 85
A comparative analysis of remdesivir and other repurposed antivirals against SARS‐CoV‐2
Alexander Simonis, Sebastian J. Theobald, Gerd Fätkenheuer, et al.
EMBO Molecular Medicine (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 80
In Vitro and In Vivo Models for Studying SARS-CoV-2, the Etiological Agent Responsible for COVID-19 Pandemic
Rafael Borges Rosa, Willyenne Marília Dantas, Jéssica Catarine Frutuoso do Nascimento, et al.
Viruses (2021) Vol. 13, Iss. 3, pp. 379-379
Open Access | Times Cited: 69
An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates
Nerea Zabaleta, Wenlong Dai, Urja Bhatt, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 9, pp. 1437-1453.e8
Open Access | Times Cited: 69
Recent advances in developing small-molecule inhibitors against SARS-CoV-2
Rong Xiang, Zhengsen Yu, Yang Wang, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 4, pp. 1591-1623
Open Access | Times Cited: 68
Animal models for SARS-CoV-2
Chung-Young Lee, Anice C. Lowen
Current Opinion in Virology (2021) Vol. 48, pp. 73-81
Open Access | Times Cited: 65
Adenosine triphosphate energy‐independently controls protein homeostasis with unique structure and diverse mechanisms
Jianxing Song
Protein Science (2021) Vol. 30, Iss. 7, pp. 1277-1293
Open Access | Times Cited: 62
Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment
Miguel Ángel Martı́nez
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 59
Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo
Zhaoyong Zhang, Eric Zeng, Lu Zhang, et al.
Cell Discovery (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 59
The interplay between emerging human coronavirus infections and autophagy
Zhenyu Zhao, Kefeng Lu, Binli Mao, et al.
Emerging Microbes & Infections (2021) Vol. 10, Iss. 1, pp. 196-205
Open Access | Times Cited: 58
Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model
C. Joaquín Cáceres, Stivalis Cárdenas-García, Silvia Carnaccini, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 57
Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action
Peter Czuppon, Florence Débarre, António Gonçalves, et al.
PLoS Computational Biology (2021) Vol. 17, Iss. 3, pp. e1008752-e1008752
Open Access | Times Cited: 55
Outside any therapeutic trial prescription of hydroxychloroquine for hospitalized patients with covid-19 during the first wave of the pandemic: A national inquiry of prescription patterns among French hospitalists
A. Bosquet, C. Affo, L. Plaisance, et al.
PLoS ONE (2022) Vol. 17, Iss. 1, pp. e0261843-e0261843
Open Access | Times Cited: 53
Autophagy-Inflammation Interplay During Infection: Balancing Pathogen Clearance and Host Inflammation
Yuqian Pang, Lanxi Wu, Cheng Tang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 39
Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture
Zixuan Yuan, Mahmud Arif Pavel, Hao Wang, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 37
Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial
Radha Rajasingham, Ananta Bangdiwala, Melanie R. Nicol, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 64
Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine
Srinivasa Reddy Bonam, Sylviane Muller, Jagadeesh Bayry, et al.
Autophagy (2020) Vol. 16, Iss. 12, pp. 2260-2266
Open Access | Times Cited: 63
Cell and animal models of SARS-CoV-2 pathogenesis and immunity
Sarah R. Leist, Alexandra Schäfer, David R. Martinez
Disease Models & Mechanisms (2020) Vol. 13, Iss. 9
Open Access | Times Cited: 58
Combining Antivirals and Immunomodulators to Fight COVID-19
Vincent Feuillet, Bruno Canard, Alain Trautmann
Trends in Immunology (2020) Vol. 42, Iss. 1, pp. 31-44
Open Access | Times Cited: 58
Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa
Emmanuel Margolin, Wendy A. Burgers, Edward D. Sturrock, et al.
Nature Reviews Microbiology (2020) Vol. 18, Iss. 12, pp. 690-704
Open Access | Times Cited: 54
Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline
Serena Bugatti, Ludovico De Stefano, Francesca Bobbio‐Pallavicini, et al.
RMD Open (2020) Vol. 6, Iss. 3, pp. e001323-e001323
Open Access | Times Cited: 54
Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients
Simon G. P. Funnell, William E. Dowling, César Muñoz‐Fontela, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 52

Scroll to top